A2A Adenosine Receptor Agonists Modulate P-gp for Brain Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The blood-brain barrier (BBB) hampers the delivery of drugs to treat neurological disorders due to its physical hindrance and efflux transporters, such as P-glycoprotein (P-gp), which limits the effectiveness of drug delivery to the brain for conditions like Alzheimer's disease and brain cancers.
Innovation Solution
Activating A2A adenosine receptors (A2A AR) with agonists like Lexiscan or NECA to inhibit P-gp expression and increase the bioavailability of chemotherapeutics by modulating P-gp-mediated efflux in brain endothelial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If physical disruption of the BBB is used to overcome drug delivery hindrance, then drug delivery to the brain is improved, but toxicity and permanent brain damage occur
Solution Approach 1:
The patent uses adenosine receptor agonists as intermediary substances that modulate P-gp expression and function. Instead of directly disrupting the BBB, the agonists act as mediators that regulate the efflux transporter activity, thereby improving drug delivery without causing the harmful effects of physical disruption methods.
Solution Approach 2:
The patent changes the expression level and activity parameters of P-glycoprotein through pharmacological modulation. By administering adenosine receptor agonists, the system dynamically adjusts P-gp expression and efflux function to optimize drug delivery while avoiding the extreme parameter changes associated with physical disruption methods.
2Reliability
If efflux transporters like P-gp are present in the BBB, then protection against harmful substances is improved, but drug delivery to the brain is hampered
Solution Approach 1:
The patent introduces dynamic regulation of P-gp expression and function through adenosine receptor agonists. Instead of static presence of efflux transporters, the system enables dynamic modulation where P-gp activity can be increased for protection and decreased for drug delivery, depending on the physiological needs and drug requirements.
Solution Approach 2:
The patent implements a feedback mechanism where adenosine receptor agonists sense and respond to the presence of substrates or physiological conditions by modulating P-gp expression and function. This feedback loop allows the BBB to adaptively regulate efflux activity, balancing protection and drug delivery needs.
3Quantity of substance
If P-gp expression is inhibited to enhance drug accumulation, then drug bioavailability is improved, but P-gp-mediated efflux function is reduced
Solution Approach 1:
The patent employs periodic or transient inhibition of P-gp expression through controlled administration of adenosine receptor agonists. Instead of permanent suppression, the system uses time-limited modulation where P-gp function is temporarily reduced to enhance drug accumulation, then restored to maintain protective efflux function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively down-regulates P-gp expression and function, enhancing the accumulation of chemotherapeutic drugs in the brain, thereby improving drug delivery and bioavailability across the BBB.
Implementation Method 1
contacting a cell expressing P-gp with a composition comprising an effective amount of an A2A adenosine receptor (A2A AR) agonist to inhibit P-gp expression in the cell
Data Source
AI summary
The present invention relates to a method of inhibiting p-glycoprotein (P-gp) expression in a cell. The method involves contacting a cell expressing P-gp with a composition comprising an effective amount of an A2A adenosine receptor (A2A AR) agonist to inhibit P-gp expression in the cell. Methods of enhancing the bioavailability of a chemotherapeutic in a subject having multi-drug resistant (MDR) cancer and methods of increasing P-gp-mediated efflux in a cell are also disclosed.